Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance

Acute myeloid leukemia (AML) is a heterogeneous disease with variable patient responses to therapy. Selinexor, an inhibitor of nuclear export, has shown promising clinical activity for AML. To identify the molecular context for monotherapy sensitivity as well as rational drug combinations, we profil...

Descripción completa

Detalles Bibliográficos
Autores principales: Emdal, Kristina B., Palacio-Escat, Nicolàs, Wigerup, Caroline, Eguchi, Akihiro, Nilsson, Helén, Bekker-Jensen, Dorte B., Rönnstrand, Lars, Kazi, Julhash U., Puissant, Alexandre, Itzykson, Raphaël, Saez-Rodriguez, Julio, Masson, Kristina, Blume-Jensen, Peter, Olsen, Jesper V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380259/
https://www.ncbi.nlm.nih.gov/pubmed/35947955
http://dx.doi.org/10.1016/j.celrep.2022.111177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380259/
https://www.ncbi.nlm.nih.gov/pubmed/35947955
http://dx.doi.org/10.1016/j.celrep.2022.111177

Ejemplares similares